Presented by expert speakers, our webinars will give you advance insight into topics that will be covered at the event.

Can’t make the date? Still register to receive the webinar recording afterwards.

Advances in Immuno-Oncology Webinars

Enabling the Expansive Interrogation of a Tumour and its Micro-environment from a Single Sample for all Precision Oncology Biomarker Discovery Applications

Wednesday 20th May | 5:00pm BST

Hosted by Robert Power, Manager, Product Management at Personalis, Inc.

  • While the success of checkpoint blockade has been hugely promising, it’s increasingly apparent that predicting response to immunotherapies and developing new ones requires a more comprehensive approach to tumor immunogenomic profiling.
  • The traditional means of generating information relating to multiple biomarkers involves the use of several assay technologies from various sources which is not only impractical given the often limited quantity of tumor samples, but also due to complexities associated with the integration and interpretation of disparate reporting formats, and can be prohibitively costly.
  • In this webinar, we’ll present our solution to these barriers, ImmunoID NeXT™, a universal cancer immunogenomics platform that consolidates multiple biomarker assays into one; providing a multidimensional view of the tumor and its microenvironment from a single sample.

Robert is the Manager of Product Management of the company’s universal cancer immunogenomics platform, ImmunoID NeXT™, for precision and immune oncology biomarker discovery applications, including TMB and MSI characterization, immune repertoire profiling, immunocellular deconvolution, tumor escape mechanisms (e.g. HLA typing and mutational status), and oncoviral detection.

Prior to joining Personalis, Robert completed an MS in Science & Technology Entrepreneurship at the University of Notre Dame and a BS in Biomedical Science at University College Dublin (UCD). Robert’s work at Notre Dame and UCD involved the development of a novel plasma-based, therapeutic biomarker signature for rare neurodegenerative disorders, as well as the investigation of an RNA-binding protein as a prognostic biomarker in colorectal cancer.

The S-TIR™ technology platform: Vaccines based on evolutionary conserved immunological mechanisms for the treatment of both allergy and cancer

Thursday 19th March | 3PM GMT

Presented by Geert Mudde, Founder, Chief Scientific Officer & Managing Director at S-TARget therapeutics.

  • How to control positive and negative checkpoints in oncology
  • The central role of plasmacytoid dendritic cells in immunological diseases
  • The induction of unprecedented polyclonal immune responses in the absence of side effects

Our free webinar is for professionals involved in Immunotherapy development  interested in learning more about immunological mechanisms for the treatment of both allergies and cancer.

This is a free event open to all, so why not register and benefit from the expertise of our speakers?

Human Studies of Inflammation, Cardiometabolic Disease and Psoriasis: A Proliferative Environment

Thursday 7th May | 1:30pm BST

Hosted by Nehal Mehta, Senior Investigator, Section of Inflammation and Cardiometabolic Diseases, NIH

  • Cardiometabolic diseases include obesity, dyslipidemia and dysglycemia, all of which increase risk of cardiovascular disease.
  • Inflammation is associated with development of cardiometabolic diseases.
  • Treatment of chronic systemic inflammation with a monoclonal antibody blocking IL1-beta improved cardiovascular outcomes and decreased incident of lung cancer.
  • Psoriasis is a chronic systemic inflammatory disease which provides a human model to better understand these observations.
Our complimentary webinar is for immunology experts interested in learning more about the latest innovations in inflammation, cardiometabolic disease and psoriasis. This is a free event open to all, so why not register and benefit from the expertise of our speaker?

Nehal Mehta attended an accelerated seven-year biomedical program where he received his B.A. in 1997 with honors and M.D. in 2001 with Distinction from The George Washington University, and a M.S.C.E. in genetic epidemiology from the University of Pennsylvania in 2009. Following medical school, Dr. Mehta did his internship, residency, and chief medical residency in internal medicine at the University of Pennsylvania Hospital, followed by a fellowship in cardiovascular diseases, nuclear cardiology, and preventive cardiology. Following this, he did a post-doctoral fellowship in genetic epidemiology with a focus on inflammation and lipoproteins at the University of Pennsylvania’s Center for Clinical Epidemiology and Biostatistics (CCEB) and Institute of Translational Medicine and Therapeutics (ITMAT). In 2009, Dr. Mehta joined the faculty in Cardiovascular Medicine at the University of Pennsylvania School of Medicine and at the CCEB as an Associate Scholar. Dr. Mehta came to the NIH in 2012 as the inaugural Lasker Clinical Research Scholar, joining the NHLBI’s Cardiovascular and Pulmonary Branch. In addition to the Lasker Scholarship, Dr. Mehta has received numerous local and national awards and honors, including being named a Fellow of the American College of Physicians and American Heart Association. He is actively involved in several foundations and organizations in membership and leadership capacities including the American Heart Association and National Psoriasis Foundation. He is the editor for the section on cardiovascular, metabolic, and lipoprotein translation in the Journal of Translational Medicine and serves as a reviewers for several international grant organizations as well as biomedical journals.

Looking for more?

All of our past webinars are available for download from our Content HUB, as well as Market Industry Reports, Q&A Sessions, Newsletters and much more.

Download Brochure

Full details regarding the Immuno Series UK are available for download in the Conference Brochure

Calling all Immunologists!

With a key priority in the IO industry centring around developing effective combination therapies, we are currently preparing a detailed market survey to provide the community with insights from leading experts into their strategies for this, the technologies they require and any bottlenecks.

Have your say in our Immuno-Oncology Market Survey & win an iPad Mini 4!